The founder contributed to a new paper in Alzheimer’s & Dementia, entitled ” CSF biomarker variability in the Alzheimer’s Association quality control program”.
The founder was a co-author on a new paper in Alzheimer’s & Dementia, entitled “Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer’s disease”.
The founder was a co-author on a publication in Journal of Alzheimer’s disease entitled “Validation of assays for measurement of Amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer’s disease treated with Solanezumab.”
A new paper, entitled “Alzheimer disease biomarker testing in Cerebrospinal Fluid: a method to harmonize assay platforms in the absence of an absolute reference standard” was published by the founder in Clinical Chemistry.
A new paper, entitled “Validation of a multiplex assay for simultaneous quantification of amyloid-beta peptide species in human plasma with utility for measurements in studies of Alzheimer’s Disease Therapeutics” was published in Journal of Alzheimer’s.
A new publication, entitled “Comparison of two analytical platforms for the clinical qualification of Alzheimer’s disease biomarkers in pathologically-confirmed dementia” was published in Journal of Alzheimer’s disease.
“A recently-published medical journal study indicates a new test exists for detecting memory loss, which could potentially help diagnose early stages of Alzheimer’s disease. Dr. Jon LaPook reports.”